Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, NSCLC, SCLC /von 2018-08-01 / Am J Cancer Res 2018;8(8):1514-1527Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, NSCLC /von 2018-06-03 / J Clin Oncol 36, 2018 (suppl; abstr 9051)Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-12-21 / BMC Cancer 2017 12;17(1):884Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC
/in Dendritic Cells, International Publications, NSCLC /von 2017-09-21 / Int. Immunopharmacol. 2017 Nov;52:197-202Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration
/in Dendritic Cells, International Publications, NSCLC /von 2017-05-03 / Clin. Cancer Res. 2017 Aug;23(16):4556-4568Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
/in Dendritic Cells, International Publications, NSCLC /von 2016-07-22 / Cancer Immunol. Immunother. 2016 09;65(9):1099-111Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma
/in Hyperthermia, International Publications, NSCLC /von 2016-06-16 / J Drug Target 2016 11;24(9):865-877Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2016-04-21 / Radiat Oncol 2016 Apr;11:60Pilot study of radiofrequency hyperthermia in combination with gefitinib in gefitinib-effective patients with advanced NSCLC
/in Hyperthermia, International Publications, NSCLC /von 2016-03-24 / Thorac Cancer 2016 Jul;7(4):422-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de